Tibet Aim Pharm (SZSE:002826) ROE % Adjusted to Book Value : 6.79% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm ROE % Adjusted to Book Value?

Tibet Aim Pharm's ROE % for the quarter that ended in Mar. 2024 was 14.94%. Tibet Aim Pharm's PB Ratio for the quarter that ended in Mar. 2024 was 2.20. Tibet Aim Pharm's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 6.79%.

Tibet Aim Pharm ROE % Adjusted to Book Value Historical Data

The historical data trend for Tibet Aim Pharm's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm ROE % Adjusted to Book Value Chart

Tibet Aim Pharm Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

1.32

1.96

2.26

2.07

2.31

Tibet Aim Pharm Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															1.64	1.10	1.78	-1.49	6.79

Competitive Comparison of Tibet Aim Pharm's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tibet Aim Pharm's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's ROE % Adjusted to Book Value falls into.

Tibet Aim Pharm ROE % Adjusted to Book Value Calculation

Tibet Aim Pharm's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	6.03%	/	2.61
	=	2.31%

Tibet Aim Pharm's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	14.94%	/	2.20
	=	6.79%

Tibet Aim Pharm ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm (SZSE:002826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines